BACKGROUND: Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity. Objectives. To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones. METHODS: In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention. RESULTS:LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation. CONCLUSIONS:LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.
RCT Entities:
BACKGROUND: Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity. Objectives. To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones. METHODS: In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention. RESULTS: LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation. CONCLUSIONS: LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.
Authors: Thomas W Storer; Lynne Magliano; Linda Woodhouse; Martin L Lee; Connie Dzekov; Jeanne Dzekov; Richard Casaburi; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: E Todd Schroeder; Atam Singh; Shalender Bhasin; Thomas W Storer; Colleen Azen; Tina Davidson; Carmen Martinez; Indrani Sinha-Hikim; S Victoria Jaque; Michael Terk; Fred R Sattler Journal: Am J Physiol Endocrinol Metab Date: 2002-09-24 Impact factor: 4.310
Authors: Thomas G Travison; Shehzad Basaria; Thomas W Storer; Alan M Jette; Renee Miciek; Wildon R Farwell; Karen Choong; Kishore Lakshman; Norman A Mazer; Andrea D Coviello; Philip E Knapp; Jagadish Ulloor; Anqi Zhang; Brad Brooks; Ahn-Hoa Nguyen; Richard Eder; Nathan LeBrasseur; Ayan Elmi; Erica Appleman; Leife Hede-Brierley; Geeta Bhasin; Ashmeet Bhatia; Antonio Lazzari; Samuel Davis; Pengsheng Ni; Lauren Collins; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2011-06-22 Impact factor: 6.053
Authors: Shalender Bhasin; Linda Woodhouse; Richard Casaburi; Atam B Singh; Ricky Phong Mac; Martin Lee; Kevin E Yarasheski; Indrani Sinha-Hikim; Connie Dzekov; Jeanne Dzekov; Lynne Magliano; Thomas W Storer Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Stephanie T Page; John K Amory; F Dubois Bowman; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; J Lisa Tenover Journal: J Clin Endocrinol Metab Date: 2004-11-30 Impact factor: 5.958
Authors: Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak Journal: Sex Med Rev Date: 2018-11-30
Authors: Richard V Clark; Ann C Walker; Susan Andrews; Philip Turnbull; Jeffrey A Wald; Mindy H Magee Journal: Br J Clin Pharmacol Date: 2017-06-10 Impact factor: 4.335
Authors: M Cesari; R Fielding; O Bénichou; R Bernabei; S Bhasin; J M Guralnik; A Jette; F Landi; M Pahor; L Rodriguez-Manas; Y Rolland; R Roubenoff; A J Sinclair; S Studenski; T Travison; B Vellas Journal: J Frailty Aging Date: 2015
Authors: Oliver Krug; Andreas Thomas; Katja Walpurgis; Thomas Piper; Gerd Sigmund; Wilhelm Schänzer; Tim Laussmann; Mario Thevis Journal: Eur J Clin Pharmacol Date: 2014-08-30 Impact factor: 2.953